What is the ROE (Return on Equity) of 4D Pharma this year?
The ROE of 4D Pharma this year is 0 undefined.
4D Pharma ROE 2025
4D Pharma ROE
0
Ticker
DDDD.L
ISIN
GB00BJL5BR07
WKN
A1XD45
In 2025, 4D Pharma's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.
4D Pharma Aktienanalyse
What does 4D Pharma do?
4D Pharma PLC was founded in 2014 and is a biopharmaceutical company specializing in the research and development of innovative therapies for microbiome-related diseases. Although the company was founded in Scotland, its headquarters are now located in Leeds, England. The business model of 4D Pharma PLC is based on understanding and manipulating the microbiome, which encompasses all microorganisms in our body. The company is working on identifying and selecting specific strains of bacteria that can help fight or even cure diseases. By using advanced sequencing and analysis technologies, 4D Pharma PLC is able to better understand the complex interaction between the microbiome and the human body, leading to the development of innovative therapeutics. 4D Pharma PLC is divided into several divisions that focus on different areas of application. For example, the "Oncology" division is working on developing therapies for various types of cancer. Special strains of bacteria are identified that can specifically target and destroy tumors. These bacteria are either injected directly into the tumor or taken in capsule form to reach the tumor site. The goal is to ultimately develop a targeted and effective cancer therapy that is less invasive and burdensome for the patient compared to traditional treatments like chemotherapy or radiation. Another division of 4D Pharma PLC is the "Autoimmunity" department, which focuses on treating autoimmune diseases such as Crohn's disease, ulcerative colitis, or multiple sclerosis. Bacterial strains are identified that can regulate the immune system and reduce the pathological immune response in autoimmune diseases. These bacteria are administered in capsules to help build a healthy gut flora and strengthen the immune system. In addition to these two divisions, 4D Pharma PLC is also working on developing therapies for various other conditions such as asthma, allergic diseases, or Parkinson's disease. One promising product is the "MRx0518" medication, which specifically stimulates the immune system and can be used in the treatment of cancer and autoimmune diseases. Overall, 4D Pharma PLC has had an impressive success story in recent years. The company has raised millions of euros in investor funding to advance its research and development efforts. It has also entered into collaborations with various partners in the pharmaceutical and biotech industries to harness the potential of bacterial therapy. The company aims to develop groundbreaking therapies for diseases where traditional treatments have limitations. 4D Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding 4D Pharma's Return on Equity (ROE)
4D Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing 4D Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
4D Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in 4D Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about 4D Pharma stock
How has the Return on Equity (ROE) of 4D Pharma developed compared to the previous year?
The ROE of 4D Pharma has increased by 0% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of 4D Pharma?
A high ROE indicates that 4D Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of 4D Pharma?
A low ROE can indicate that 4D Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of 4D Pharma affect the company?
A change in ROE (Return on Equity) of 4D Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of 4D Pharma?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of 4D Pharma?
Some factors that can influence 4D Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does 4D Pharma pay?
Over the past 12 months, 4D Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 4D Pharma is expected to pay a dividend of 0 GBP.
What is the dividend yield of 4D Pharma?
The current dividend yield of 4D Pharma is .
When does 4D Pharma pay dividends?
4D Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of 4D Pharma?
4D Pharma paid dividends every year for the past 0 years.
What is the dividend of 4D Pharma?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is 4D Pharma located?
4D Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von 4D Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of 4D Pharma from 2/7/2025 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 2/7/2025.
When did 4D Pharma pay the last dividend?
The last dividend was paid out on 2/7/2025.
What was the dividend of 4D Pharma in the year 2024?
In the year 2024, 4D Pharma distributed 0 GBP as dividends.
In which currency does 4D Pharma pay out the dividend?
The dividends of 4D Pharma are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von 4D Pharma
Our stock analysis for 4D Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 4D Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
